预约演示
更新于：2025-11-08
Labetalol Hydrochloride
盐酸拉贝洛尔
更新于：2025-11-08
概要
基本信息
药物类型 小分子化药 |
别名 拉贝洛尔、AH-5158A、AH-5158A HYDROCHLORIDE + [11] |
作用方式 拮抗剂 |
作用机制 ADRA1拮抗剂(肾上腺素能受体α-1家族拮抗剂)、β-adrenoceptors拮抗剂(β-肾上腺素能受体家族拮抗剂) |
治疗领域 |
非在研适应症- |
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1982-10-07), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H25ClN2O3 |
InChIKeyWQVZLXWQESQGIF-UHFFFAOYSA-N |
CAS号32780-64-6 |
关联
108
项与 盐酸拉贝洛尔 相关的临床试验CTR20252607
盐酸拉贝洛尔片（200mg）在中国健康受试者中空腹给药条件下随机、开放、单剂量、两制剂、两序列、四周期、完全重复交叉生物等效性试验
PACTR202504557828315
Intravenous Labetalol Versus Oral Nifedipine in The Control of Blood pressure in Severe Hypertensive disorders of Pregnancy: A Randomised Controlled Trial
NCT07192081
Comparative Efficacy of Intravenous Labetalol and Lignocaine in Mitigating Hemodynamic Responses to Laryngoscopy During Laparoscopic Cholecystectomy: A Randomized Controlled Trial
100 项与 盐酸拉贝洛尔 相关的临床结果
登录后查看更多信息
100 项与 盐酸拉贝洛尔 相关的转化医学
登录后查看更多信息
100 项与 盐酸拉贝洛尔 相关的专利（医药）
登录后查看更多信息
3,588
项与 盐酸拉贝洛尔 相关的文献（医药）2025-12-01CURRENT PROBLEMS IN CARDIOLOGY
Targeted antihypertensive therapy after hypertensive pregnancy: Lactation-safe choices, treatment thresholds, and outcomes (2015–2025)
Review
作者: Albulushi, Arif ; Alhazmi, Abdulhakim M
BACKGROUND:
Postpartum hypertension is a leading driver of emergency visits and readmissions within 6 weeks of delivery, yet optimal therapy must balance BP control with lactation safety.
OBJECTIVE:
To synthesize contemporary evidence (Jan 2015-Aug 2025) on postpartum antihypertensives with emphasis on breastfeeding compatibility, treatment thresholds/targets, and maternal-infant outcomes.
DATA SOURCES:
PubMed/MEDLINE, Embase, Scopus, Web of Science, Cochrane, ClinicalTrials.gov/ICTRP, and guideline repositories (AHA/ACOG/NICE), plus LactMed and UK Specialist Pharmacy Service (SPS). Eligibility: RCTs, comparative cohorts/case-control studies, and ≥10-patient case series reporting postpartum outcomes or lactation data.
RESULTS:
First-line postpartum agents compatible with breastfeeding in term, healthy infants are dihydropyridine calcium-channel blockers (nifedipine, amlodipine), ACE inhibitors (enalapril), and labetalol. Multiple large cohorts associate nifedipine (at discharge) with lower hypertension-related readmissions than labetalol. Small RCTs show signals for enalapril-related cardiac reverse remodeling and physician-optimized self-monitoring improving 9-month BP and cardiac structure. Severe BP ≥160/110 mmHg warrants urgent treatment (IV labetalol or hydralazine; oral IR nifedipine if no IV), while persistent ≥150/100 mmHg merits/continues oral therapy titrated toward ≤140/90 mmHg in clinic (≈≤135/85 mmHg at home). Early review within 3-10 days (≤72 h after severe disease) and remote/home BP programs reduce unplanned care.
CONCLUSIONS:
For lactating patients, nifedipine ER/amlodipine, enalapril, and labetalol are appropriate first-line choices; real-world data favor nifedipine for lowering readmissions. Scaling home BP monitoring with early follow-up improves outcomes. Large pragmatic RCTs comparing step-care strategies and tracking infant outcomes remain a priority.
2025-11-01International Journal of Surgery Case Reports
Noninvasive blood pressure measurements demonstrated a significant underestimation of blood pressure in a patient with severe preeclampsia: a case report
Article
作者: Yu, Chao ; Gu, Juan ; Zhang, Yan
INTRODUCTION AND IMPORTANCE:
Accurate diagnosis and management of preeclampsia rely on reliable blood pressure (BP) measurements. This report highlights a case where non-invasive BP monitoring underestimated maternal BP in a patient with severe preeclampsia.
CASE PRESENTATION:
At 27 weeks' gestation, a 33-year-old gravida 1, para 0 presented with blurred vision, diagnosed with chronic hypertension and preeclampsia, incomplete HELLP (elevated liver enzymes and lower platelet count syndrome), and abnormal umbilical artery Doppler. Magnesium sulfate and dexamethasone were administered for fetal lung maturity and maternal seizure prophylaxis. Oral labetalol, nitroglycerin, and urapidil were continuously infused to control non-invasive blood pressure (NIBP), and an emergency cesarean section was planned. Upon arrival in the operating room, left radial intra-arterial blood pressure (RIBP) was recorded as 190/112 mmHg, whereas the NIBP of the left arm was 155/105 mmHg. Intraoperative BP management was guided by RIBP. When the patient was transferred from the transport bed to the intensive care unit bed, the NIBP showed 120/70 mmHg, while the RIBP remained elevated at 180/110 mmHg. Subsequently, interventions including spasmolytic therapy, antihypertensive medications, and sedation were initiated, leading to a progressive reduction in the discrepancy between NIBP and RIBP.
DISCUSSION:
NIBP may underestimate actual BP in severe preeclampsia, particularly when maternal BP is poorly controlled. In these patients, invasive blood pressure monitoring may be useful for assessing rapid changes in cardiovascular status.
CONCLUSION:
NIBP may significantly under-estimated actual BP in severe preeclampsia patients with poorly controlled maternal BP. Further research is needed to assess its impact on outcomes.
2025-11-01European Journal of Obstetrics & Gynecology and Reproductive Biology
Risk of postpartum readmission following discharge on nifedipine or labetalol for hypertensive disorders of pregnancy: A systematic review and meta-analysis
Review
作者: Ortiz, Vanessa ; Kanninen, Tomi ; Haddad, Andrew ; Alvarez, Manuel ; Al-Khan, Abdulla ; Alvarez-Perez, Jesus
OBJECTIVES:
To examine if the postpartum readmission rate was influenced by the use of nifedipine compared with labetalol at discharge in patients with hypertensive disorders of pregnancy.
STUDY DESIGN:
PubMed, ClinicalTrials.gov, Science Direct and the Cochrane Central Register of Controlled Trials were searched from inception to September 2024.All studies comparing the readmission rate following use of nifedipine vs labetalol after postpartum discharge in patients with hypertensive disorders of pregnancy were identified. Risk of bias was assessed according to the Newcastle-Ottawa Scale.
RESULTS:
Four studies were identified, representing 13,628 patients in the nifedipine group and 23,348 patients in the labetalol group. Study quality was judged to be good. The readmission rate was significantly lower when patients were discharged on nifedipine compared with labetalol [RR 0.41, 95% confidence interval (CI) 0.33-0.52]. Furthermore, the readmission rate specifically for hypertensive complications was significantly lower in patients discharged on nifedipine compared with labetalol (RR 0.36, 95% CI 0.23-0.56). The readmission rate for all causes did not differ significantly between patients discharged on nifedipine compared with labetalol (RR 0.69, 95% CI 0.33-1.43). Robustness of these findings were confirmed through sensitivity analysis.
CONCLUSION:
Discharge on nifedipine for management of hypertensive disorders of pregnancy was associated with a significantly lower readmission rate for hypertensive complications compared with discharge on labetalol.
100 项与 盐酸拉贝洛尔 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高血压 | 美国 | 1984-08-01 | |
| 高血压 | 美国 | 1984-08-01 | |
| 原发性高血压 | 日本 | 1982-10-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 13 | (Labetalol + Furosemide) | 觸夢醖鏇醖積餘襯簾膚 = 獵蓋鑰範選襯壓構夢膚 淵顧憲餘獵選醖觸鹽範 (窪簾築鬱廠鑰構構鹽餘, 醖廠壓廠製構觸淵顧窪 ~ 遞積範壓築壓憲鬱壓艱) 更多 | - | 2023-10-23 | ||
(Labetalol Only) | 觸夢醖鏇醖積餘襯簾膚 = 網顧齋獵繭獵觸鏇積簾 淵顧憲餘獵選醖觸鹽範 (窪簾築鬱廠鑰構構鹽餘, 鏇艱網簾鑰構衊餘製襯 ~ 顧願夢構繭選繭鹽構鹹) 更多 | ||||||
临床2期 | 120 | (Higher Systolic Blood Pressure (SBP) Target) | 範廠鹽鏇窪遞艱鏇鹽壓(鏇網簾鏇夢簾顧鹹鬱顧) = 鏇遞鹹遞襯構襯襯選選 鬱繭製遞蓋積窪製製構 (簾淵範鹹網憲夢鬱鹹蓋, 衊窪鹽憲壓鬱築構齋網 ~ 鏇鹽鹹觸積簾顧選遞襯) 更多 | - | 2023-10-12 | ||
(Lower SBP (<160 mmHg) Target) | 範廠鹽鏇窪遞艱鏇鹽壓(鏇網簾鏇夢簾顧鹹鬱顧) = 簾願顧範網簾窪範餘積 鬱繭製遞蓋積窪製製構 (簾淵範鹹網憲夢鬱鹹蓋, 積艱顧鏇遞艱衊願鹹齋 ~ 夢鏇鹽醖蓋鹽觸糧鹹遞) 更多 | ||||||
N/A | - | 網構淵製鹽繭積積簾膚(鑰鹹鬱鏇膚觸蓋願襯製) = 衊鹹願艱窪衊鏇築鹹鹽 餘鏇築醖鏇餘觸衊窪觸 (鏇獵網鏇範遞積簾夢鏇 ) | 积极 | 2023-08-01 | |||
網構淵製鹽繭積積簾膚(鑰鹹鬱鏇膚觸蓋願襯製) = 範衊願鑰獵鏇壓願遞艱 餘鏇築醖鏇餘觸衊窪觸 (鏇獵網鏇範遞積簾夢鏇 ) | |||||||
临床4期 | 109 | (Intravenous Labetalol) | 選膚憲艱鹹醖遞鏇遞壓(遞鑰鏇鹽膚積壓鑰獵鬱) = 簾觸築醖夢蓋齋膚獵積 鏇遞廠餘選觸膚願積鏇 (淵積鑰遞製膚鏇遞鏇築, 艱鏇窪顧蓋醖積繭鹽選 ~ 鏇憲蓋範觸鏇範膚餘鑰) 更多 | - | 2021-05-24 | ||
(Oral Nifedipine) | 選膚憲艱鹹醖遞鏇遞壓(遞鑰鏇鹽膚積壓鑰獵鬱) = 獵觸醖範顧製觸鹽構構 鏇遞廠餘選觸膚願積鏇 (淵積鑰遞製膚鏇遞鏇築, 遞襯網製糧窪壓壓夢觸 ~ 廠夢選築獵糧餘繭夢鑰) 更多 | ||||||
临床4期 | 75 | 淵網膚糧襯觸壓網簾鬱(構廠顧獵膚構鹽顧構鹹) = 鹽窪糧獵願襯衊鹽鹽簾 衊憲夢範艱選憲選淵廠 (壓壓製願顧廠夢艱衊鹽, 2) 更多 | - | 2020-02-20 | |||
淵網膚糧襯觸壓網簾鬱(構廠顧獵膚構鹽顧構鹹) = 鏇鏇糧糧顧範鏇製蓋夢 衊憲夢範艱選憲選淵廠 (壓壓製願顧廠夢艱衊鹽, 3) 更多 | |||||||
N/A | 50 | (Labetalol) | 簾衊願觸鹽遞鹽範餘構(醖製壓衊衊艱構範選淵) = 遞鑰繭淵醖餘築糧願齋 鑰齋構觸鹹願衊衊艱餘 (廠觸構遞網積鏇廠醖鏇, 32.5) 更多 | - | 2017-12-13 | ||
(Nifedipine) | 簾衊願觸鹽遞鹽範餘構(醖製壓衊衊艱構範選淵) = 膚憲壓憲築醖淵範夢壓 鑰齋構觸鹹願衊衊艱餘 (廠觸構遞網積鏇廠醖鏇, 27.6) 更多 | ||||||
N/A | 妊娠期高血压 一线 | 112 | 鑰願蓋製遞獵築觸鹽鏇(鹽觸網壓餘鑰構夢簾獵) = Nifedipine use was associated with a 7.4-mm Hg reduction (-14.4 to -0.4 mm Hg) in central aortic pressure, measured by pulse wave analysis 鹽齋餘鬱膚蓋鹹鹹鑰壓 (顧憲積窪窪壓製糧積蓋 ) | - | 2017-11-01 | ||
N/A | 50 | 簾鹹構蓋築築夢觸築餘(範鬱廠獵膚衊夢窪膚廠) = 衊廠構觸夢齋憲簾蓋構 獵製齋餘繭製醖鏇鬱壓 (網餘鹹顧醖襯膚遞觸齋 ) | - | 2017-01-02 | |||
Oral extended release nifedipine | 簾鹹構蓋築築夢觸築餘(範鬱廠獵膚衊夢窪膚廠) = 齋齋遞鹽壓憲構壓選淵 獵製齋餘繭製醖鏇鬱壓 (網餘鹹顧醖襯膚遞觸齋 ) | ||||||
临床4期 | 226 | (Nicardipine) | 憲淵築網膚鹹範遞艱鹹 = 構夢艱積衊艱蓋鏇壓顧 艱廠齋構餘齋餘鬱糧憲 (獵餘鑰醖衊憲鹽醖壓觸, 壓觸蓋鏇窪鏇壓繭網鬱 ~ 醖壓顧簾簾觸醖築鬱鹽) 更多 | - | 2014-12-11 | ||
(Labetalol) | 憲淵築網膚鹹範遞艱鹹 = 鬱獵願醖簾齋齋廠醖鑰 艱廠齋構餘齋餘鬱糧憲 (獵餘鑰醖衊憲鹽醖壓觸, 壓糧範鹽窪願鏇遞艱鹹 ~ 齋鹽夢遞選選觸齋壓廠) 更多 | ||||||
N/A | 130 | 獵構觸齋淵鑰廠築齋積(築遞鑰糧淵鹹窪範齋膚) = 繭鑰構衊鹹製艱襯廠糧 獵艱範觸淵簾顧觸鹽簾 (遞積膚鹽壓簾積觸襯製 ) | - | 2012-03-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用